Skip to content

Category: QB3Syndicate content

Slicing the Pie: Entity Formation and the Division of Equity

 
Slicing the Pie: Entity Formation and the Division of Equity
qed@qb3 - UCB
Friday, March 5, 2010
12:00 to 1:00 pm
Stanley Hall Room 621

Matt Kirmayer will lead a discussion of the issues relating to forming an entity, seeding it with the assets and IP to be successful, and avoiding the potential pitfalls  when dividing up the equity among the founders.

Speakers

Matt Kirmayer is a member in the Corporate practice. His practice is focused on the representation of emerging technology companies, venture capital and private equity funds and institutional investors.  Matt represents clients in many industries, such as multimedia, wireless technologies, networking, internet infrastructure and security, nanotechnology, life sciences and medical devices. He also represents NY Money Center Banks and institutional investors in capital market transactions. Prior to joining Mintz Levin, Matt was a partner at a San Francisco area law firm. Matt began his career in New York City handling securities offerings and merger and acquisition transactions. Matt is admitted to practice law in California and New York.  He received a J.D. from Rutgers University and an LL.M. from New York University School of Law.

Lunch provided, but space is limited so please reserve a seat here.

http://qb3.org/services/qed-qb3/?searchterm=qed

...But what do I know? Lessons learned from living through a couple of spin-out companies

...But what do I know?
Lessons learned from living through a couple of spin-out companies
qed@qb3 UCSF
Thursday, March 4, 2010
12:00 to 1:00 pm
Byers Hall Room 212

There are many lessons to be learned in the formation of spinouts. Tom will walk through his experiences going from an academic setting to a spinout company and what he has learned from this and a couple of other companies that he has been close to (Avantome, TrueMaterials, Boreal Genomics)

Speakers

Tom Willis is the CEO of MLC Dx Inc. a VC backed company dedicated to the commercialization of molecular diagnostic tests. Prior to founding MLC, Tom has been an entrepreneur in the biotech industry for the past decade. After receiving his Ph.D. in physics from Stanford University, he joined the Stanford Genome Technology Center (SGTC) to work on DNA sequence analysis technologies. He held several positions at the SGTC including Associate Director in charge of technology development. While at SGTC, he co-invented the Molecular Inversion Probe technology for high throughput genotyping. In 2001, he co-founded ParAllele BioScience to develop and commercialize this technology. As its founding CEO, he led ParAllele through two rounds of VC financing a grew the company to over 80 employees. In 2005 ParAllele was acquired by Affymetrix at which time Tom served in several management positions at Affymetrix. He left in 2007 to pursue new startup opportunities. In addition to his role at MLC, Tom serves on the boards of SpinX Technologies and Boreal Genomics

Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=198455

http://qb3.org/services/qed-qb3/?searchterm=qed

Secrets of NIH SBIR and STTR grant applications

 

 

Gregory Milman, Ph.D., Director of the Office for Innovation and Special Programs in NIAID
Also: A panel discussion by award winners
2-4 pm on January 13 in Byers Auditorium, Genentech Hall
Reception to follow in the atrium
 
SBIR and STTR funding can provide critical early stage support for successful bioscience companies. Indeed, many of the companies in the QB3 Mission Bay Incubator Network used SBIR funding to move from lab to startup. This seminar will unpack the secrets of what it takes to maximize your chances of success. Greg Milman oversees the NIAID’s $100M/year SBIR and STTR program.
Register online through our website at http://www.qb3.org

Angel Investment in High-Tech

Angel Investment in High-Tech
 
qed@qb3 - UCB
Friday, January 8, 2010
12:00 to 1:00 pm
Stanley Hall Room 621

The Value of Versatility for an Engineer Leading a Startup

The Value of Versatility 
for an Engineer Leading a Startup
qed@qb3 - UCB
Friday, December 4, 2009
12:00 to 1:00 pm
Stanley Hall Room 621

PR goes Viral

PR goes Viral
qed@qb3 - UCSF

Thursday, December 3, 2009
12:00 to 1:00 pm
Byers Hall Room 212

 

Navigating the Life Science Venture Industry

Navigating the Life Science
Venture Industry
qed@qb3 - UCB

Friday, November 6, 2009
12:00 to 1:00 pm
Stanley Hall Room 621

Seed Fund for UC Bioscience Companies Launches at Mission Bay

UC SAN FRANCISCO
 
Corinna Kaarlela, News Director
Source: Kristen Bole (415) 476-2557
E-mail: kbole@pubaff.ucsf.edu
Web: www.ucsf.edu
 
FOR IMMEDIATE RELEASE
October 26, 2009

The California Institute of Quantitative Biosciences (QB3) is collaborating with a newly launched $7.5 million fund to provide startup capital for University of California bioscience entrepreneurs and a long-term endowment for QB3.

Coming to Terms with your Term Sheet

Coming to Terms with your Term Sheet
Speakers: Thomas E. Duley, Attorney, Morgan Lewis
Sarita K. Jain, PhD, J&J Venture Investments
qed@qb3 - UCSF

Thursday, November 5, 2009
12:00 to 1:00 pm
Byers Hall Room 212

AdaptiveThemes